Bictegravir/lenacapavir (Bixlenvo) vs Raltegravir
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV integrase · full HIV pipeline
Bictegravir/lenacapavir (Bixlenvo)
Marketed by Gilead Sciences
NCT05502341 · Phase 2/3 · active, not recruiting
This was a randomized, active-controlled trial in 557 people in its Phase 3 part, but it was open-label, so participants and investigators knew which treatment each person received. Its primary endpoint, the proportion with detectable HIV-1 RNA at week 48, is an objective laboratory measure, and bictegravir/lenacapavir met the non-inferiority goal against continued complex regimens.
Next expected readout: July 2028 · NCT07908446 (registry estimate)
Reported efficacy
Phase 2: Percentage of Participants With Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) ≥ 50 Copies/mL at Week 24 as Determined by the United States Food and Drug Administration (US FDA) Defined Snapshot Algorithm; Phase 3: Percentages of Participants With HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the US FDA-defined Snapshot Algorithm: Phase 3 primary, HIV-1 RNA >=50 copies/mL at week 48 (FDA snapshot): BIC/LEN 0.8% (n=371) vs stable baseline regimen 1.1% (n=186), difference -0.3% (95.002% CI -2.3% to 1.8%); Gilead states the non-inferiority criterion was met. Phase 2 week 24: 0% and 1.9% vs 0% (CT.gov posted results). (met)
Result source: NCT05502341
Raltegravir · Isentress
Marketed by Merck & Co.
NCT00293254 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with 351 patients, using HIV-1 RNA suppression - a regulator-accepted, disease-defining measure - as the primary endpoint. The raltegravir arm showed clearly higher suppression rates than placebo at both Week 16 and Week 48, with confidence intervals that do not overlap, indicating a statistically robust and clinically meaningful benefit.
Next expected readout: January 2028 · NCT02140255 (registry estimate)
Reported efficacy
Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16 (16 Weeks); Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 48 (48 Weeks); Double-Blind Extension - Week 156: Percentage of Participants Achieving HIV RNA <400 Copies/mL (156 Weeks); Open-Label Extension - Week 240: Percentage of Participants Achieving HIV RNA <400 Copies/mL (240 Weeks): Percentage of Participants Achieving HIV RNA <400 Copies/mL at Week 16 (16 Weeks): Raltegravir 400 mg b.i.d. + OBT 77.3% (95% CI 71.3 to 82.6) vs Placebo + OBT 42.9% (95% CI 33.8 to 52.3) (met)
Result source: NCT00293254
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Bictegravir/lenacapavir (Bixlenvo) | Raltegravir |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | —Trial running · NCT06532656 | —Not posted · NCT01195467 |
| HIV-1 RNA 50 copies/mL or more (week 48) | —Trial running · NCT06532656 | —Not posted · NCT01195467 |
| CD4 count, change (week 48) | —Trial running · NCT06532656 | 157.2 vs 54.2+103 vs placeboNCT002932546 other results
|
HIV-1 RNA below 50 copies/mL (week 48)
- Bictegravir/lenacapavir (Bixlenvo)
- —Trial running · NCT06532656
- Raltegravir
- —Not posted · NCT01195467
HIV-1 RNA 50 copies/mL or more (week 48)
- Bictegravir/lenacapavir (Bixlenvo)
- —Trial running · NCT06532656
- Raltegravir
- —Not posted · NCT01195467
CD4 count, change (week 48)
- Bictegravir/lenacapavir (Bixlenvo)
- —Trial running · NCT06532656
- Raltegravir
- 157.2 vs 54.2+103 vs placeboNCT00293254
6 other results
- 170.9 vs 71.0 NCT00293267
- 98.4 vs 39.8 NCT00293254
- 120.2 vs 49.4 NCT00293267
- 8.6 vs 21.9 NCT00772590
- 2.7 vs 21.9 NCT00772590
- 192 vs 205 NCT00762892
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Bictegravir/lenacapavir (Bixlenvo): 0 of 4 rows · Raltegravir: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Raltegravir |
|---|---|
| Dropout rate | 23.7%400 mg b.i.d.a NCT00293254 · Phase 3 · combination show 27 more results—400 mg b.i.d. NCT00293254 · Phase 3 · combination —400 mg b.i.d NCT00293267 · Phase 3 · combination 17.5%400 mg b.i.d NCT00293267 · Phase 3 · combination 25.5%400 mg b.i.d. NCT00369941 · Phase 3 15.4% NCT01147107 · Phase 4 · registry result, not featured evidence 9.5% NCT03374358 · Phase 4 · registry result, not featured evidence 0% NCT03667547 · Phase 4 · registry result, not featured evidence —Arm A Raltegravir NCT03205566 · Phase 4 · registry result, not featured evidence —Arm B Raltegravir Lamivudine NCT03205566 · Phase 4 · registry result, not featured evidence · combination 10.5% NCT02383355 · Phase 4 · registry result, not featured evidence 38.5% NCT00939874 · Phase 4 · registry result, not featured evidence 0% NCT00843713 · Phase 4 · registry result, not featured evidence 22.2% NCT01332227 · Phase 4 · registry result, not featured evidence · combination 27.3% NCT00870363 · Phase 4 · registry result, not featured evidence · combination 6.7%Switch to Tenofovir/Emtricitabine NCT01270802 · Phase 4 · registry result, not featured evidence · combination —Switch to Tenofovir/Emtricitabine/ NCT01270802 · Phase 4 · registry result, not featured evidence 35.7% NCT00762892 · Phase 4 · registry result, not featured evidence 0% NCT01335620 · Phase 4 · registry result, not featured evidence · combination 6.7%Intervention Arm No.1 NCT00931801 · Phase 4 · registry result, not featured evidence · combination 28.6%Intervention Arm No.2 NCT00931801 · Phase 4 · registry result, not featured evidence · combination 0%Hyper-immune Bovine Colostrum NCT00772590 · Phase 4 · registry result, not featured evidence 0%Raltegravir + Hyper-immune Bovine NCT00772590 · Phase 4 · registry result, not featured evidence · combination 0% NCT00631449 · Phase 4 · registry result, not featured evidence 7.5%1200 mg QD NCT03029689 · Phase 3 · registry result, not featured evidence · combination 4.1% NCT02284035 · Phase 3 · registry result, not featured evidence · combination —1200 mg QD + Truvada NCT02131233 · Phase 3 · registry result, not featured evidence · combination 12.4%Reformulated Raltegravir NCT02131233 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | 0.9%400 mg b.i.d.a NCT00293254 · Phase 3 · combination show 27 more results—400 mg b.i.d. NCT00293254 · Phase 3 · combination —400 mg b.i.d NCT00293267 · Phase 3 · combination 0.4%400 mg b.i.d NCT00293267 · Phase 3 · combination 5%400 mg b.i.d. NCT00369941 · Phase 3 — NCT01147107 · Phase 4 · registry result, not featured evidence — NCT03374358 · Phase 4 · registry result, not featured evidence — NCT03667547 · Phase 4 · registry result, not featured evidence —Arm A Raltegravir NCT03205566 · Phase 4 · registry result, not featured evidence —Arm B Raltegravir Lamivudine NCT03205566 · Phase 4 · registry result, not featured evidence · combination 10.5% NCT02383355 · Phase 4 · registry result, not featured evidence — NCT00939874 · Phase 4 · registry result, not featured evidence — NCT00843713 · Phase 4 · registry result, not featured evidence 5.6% NCT01332227 · Phase 4 · registry result, not featured evidence · combination — NCT00870363 · Phase 4 · registry result, not featured evidence · combination 0%Switch to Tenofovir/Emtricitabine NCT01270802 · Phase 4 · registry result, not featured evidence · combination —Switch to Tenofovir/Emtricitabine/ NCT01270802 · Phase 4 · registry result, not featured evidence — NCT00762892 · Phase 4 · registry result, not featured evidence — NCT01335620 · Phase 4 · registry result, not featured evidence · combination 0%Intervention Arm No.1 NCT00931801 · Phase 4 · registry result, not featured evidence · combination 7.1%Intervention Arm No.2 NCT00931801 · Phase 4 · registry result, not featured evidence · combination —Hyper-immune Bovine Colostrum NCT00772590 · Phase 4 · registry result, not featured evidence —Raltegravir + Hyper-immune Bovine NCT00772590 · Phase 4 · registry result, not featured evidence · combination — NCT00631449 · Phase 4 · registry result, not featured evidence —1200 mg QD NCT03029689 · Phase 3 · registry result, not featured evidence · combination — NCT02284035 · Phase 3 · registry result, not featured evidence · combination —1200 mg QD + Truvada NCT02131233 · Phase 3 · registry result, not featured evidence · combination 1.3%Reformulated Raltegravir NCT02131233 · Phase 3 · registry result, not featured evidence |
| Serious AEs | —400 mg b.i.d.a NCT00293254 · Phase 3 · combination show 27 more results34.8%400 mg b.i.d. NCT00293254 · Phase 3 · combination 41.8%400 mg b.i.d NCT00293267 · Phase 3 · combination —400 mg b.i.d NCT00293267 · Phase 3 · combination 20.3%400 mg b.i.d. NCT00369941 · Phase 3 21.1% NCT01147107 · Phase 4 · registry result, not featured evidence 0% NCT03374358 · Phase 4 · registry result, not featured evidence 0% NCT03667547 · Phase 4 · registry result, not featured evidence 0%Arm A Raltegravir NCT03205566 · Phase 4 · registry result, not featured evidence 0%Arm B Raltegravir Lamivudine NCT03205566 · Phase 4 · registry result, not featured evidence · combination 0% NCT02383355 · Phase 4 · registry result, not featured evidence 13.5% NCT00939874 · Phase 4 · registry result, not featured evidence 3.8% NCT00843713 · Phase 4 · registry result, not featured evidence 5.6% NCT01332227 · Phase 4 · registry result, not featured evidence · combination 0% NCT00870363 · Phase 4 · registry result, not featured evidence · combination —Switch to Tenofovir/Emtricitabine NCT01270802 · Phase 4 · registry result, not featured evidence · combination 0%Switch to Tenofovir/Emtricitabine/ NCT01270802 · Phase 4 · registry result, not featured evidence 7.1% NCT00762892 · Phase 4 · registry result, not featured evidence 0% NCT01335620 · Phase 4 · registry result, not featured evidence · combination 13.3%Intervention Arm No.1 NCT00931801 · Phase 4 · registry result, not featured evidence · combination 14.3%Intervention Arm No.2 NCT00931801 · Phase 4 · registry result, not featured evidence · combination 0%Hyper-immune Bovine Colostrum NCT00772590 · Phase 4 · registry result, not featured evidence 5.3%Raltegravir + Hyper-immune Bovine NCT00772590 · Phase 4 · registry result, not featured evidence · combination 0% NCT00631449 · Phase 4 · registry result, not featured evidence 0%1200 mg QD NCT03029689 · Phase 3 · registry result, not featured evidence · combination 6.1% NCT02284035 · Phase 3 · registry result, not featured evidence · combination 9.6%1200 mg QD + Truvada NCT02131233 · Phase 3 · registry result, not featured evidence · combination —Reformulated Raltegravir NCT02131233 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | 400 mg b.i.d.a upper respiratory tract infection 33% (placebo 24.4%) diarrhoea 32.6% (placebo 29.4%) fatigue 19.6% (placebo 15.1%) NCT00293254 · Phase 3 · combination show 17 more results400 mg b.i.d diarrhoea 31.9% (placebo 28.8%) nasopharyngitis 25% (placebo 17.8%) bronchitis 18.1% (placebo 13.6%) NCT00293267 · Phase 3 · combination alt elevation 55.3% NCT01147107 · Phase 4 · registry result, not featured evidence sleeping difficulties 52.6% (placebo 54.2%) gastrointestinal (diarrhoea, nausea) 47.4% (placebo 29.2%) headache 47.4% (placebo 33.3%) NCT03374358 · Phase 4 · registry result, not featured evidence runny nose 10.5% cold 5.3% diarrhoea 5.3% NCT03205566 · Phase 4 · registry result, not featured evidence nightmares and vivid dreams 13.2% diarrhoea 7.9% headache 7.9% NCT03205566 · Phase 4 · registry result, not featured evidence · combination upper respiratory tract infection 18.9% diarrhoea 10.8% abdominal cramps 5.4% NCT00939874 · Phase 4 · registry result, not featured evidence hyperbilirubinemia 3.8% (placebo 0%) NCT00843713 · Phase 4 · registry result, not featured evidence hyperbilirubinaemia 8.3% ocular icterus 8.3% bronchitis 5.6% NCT01332227 · Phase 4 · registry result, not featured evidence · combination gastrointestinal intolerance 9.1% neuropsychiatric side effect 0% NCT00870363 · Phase 4 · registry result, not featured evidence · combination neutropenia 6.7% diastolic hypertension 0% impaired fasting glucose 0% NCT01270802 · Phase 4 · registry result, not featured evidence bronchitis 20% diarrhea 20% headache 20% NCT00931801 · Phase 4 · registry result, not featured evidence · combination diarrhea 21.4% upper respiratory infection 21.4% fatigue 14.3% NCT00931801 · Phase 4 · registry result, not featured evidence · combination 1200 mg QD adverse event not related to the treatment 2.6% (placebo 5.6%) NCT03029689 · Phase 3 · registry result, not featured evidence · combination insomnia 8.2% amigdalitis 6.1% common cold 6.1% NCT02284035 · Phase 3 · registry result, not featured evidence · combination 1200 mg QD + Truvada headache 15.8% nausea 13.6% diarrhoea 13.4% NCT02131233 · Phase 3 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Raltegravir
show 5 more results
show 1 more result
show 5 more results
show 1 more result
show 6 more results
show 1 more result
show 8 more results
show 1 more result
show 7 more results
show 3 more results
+ 22 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bictegravir/lenacapavir (Bixlenvo)'s landscape · Raltegravir's landscape